SP1-41 Five-year survival of patients with non-Hodgkin's lymphoma submitted to haematopoietic stem cell transplantation in a reference centre in Brazil

Introduction Since the 990s, haematopoietic stem cell transplantation (HSCT) is being used more frequently in the treatment of patients with non-Hodgkin9s lymphoma (NHL). Methods This study was conducted in a historical cohort of adult patients with NHL undergoing first HSCT in a referral hospital in Rio de Janeiro (1997–2009). The Kaplan–Meier method was used for comparison between strata of covariates and Cox regression for multivariate analysis. Results In the study period 100 patients underwent HSCT. Of these, 61 were male, with a median age of 45. Predominant subtype at transplantation was Diffuse Large B Cell Lymphoma (82%). The median time between diagnosis and transplantation was 17 months. At 5 years, the probability of overall survival was 50.8% and survival free of evidence of disease was 54.2%. Patients with advanced stage (III/IV) at diagnosis (61.9% vs 31.8%); those with bulky disease (60.6% vs 36.7%) and those without evidence of disease at 12 months post transplantation (67.5% vs 5.7%) had higher survival. In multivariate analysis, evidence of disease at 12 months after HSCT (HR 5.22), chemo-sensitivity to the last regimen (HR 6.81) and systemic symptoms (HR 2.60) were associated to survival. Conclusions We found that the most well recognised disease characteristics and overall survival in this cohort were similar to those found for patients with NHL undergoing haematopoietic stem cell transplantation in other countries.